Telix completes $51m acquisition of Texan biotech

2 minute read


The buy broadens Telix’s reach into osteosarcoma, including in children.


The buy broadens Telix’s reach into osteosarcoma, including in children.

This content is for Health Services Daily subscribers only.
or Join Now.

End of content

No more pages to load

Log In Register ×